April 28, 2020
1 pm
Sponsored by
Webinar Description:
The demand for access to less invasive biopsy methods for cancer presents a critical decision for many provider laboratories. At what testing volume does the desire for data, reimbursement, and patient
retention cross the tipping point for bringing testing in-house? How feasible is it for smaller local laboratories to acquire and maintain the laboratory and informatics infrastructure required to perform these tests? How much time and resources
should be dedicated to making such a transition? In this webinar, Mr. Brady Davis MBA and Dr. Anna Lapuk, outline the pros and cons for bringing plasma testing in-house vs. send out services for oncology testing, suggest when organizations
might find the transition most beneficial, and outline the process for transitioning from send out to in-house testing. Critical factors for consideration such as staffing, oncologist and pathologist outreach and education, LIMS and data ecosystem
integration, and clinical reporting will be presented.
Learning Objectives:
- Decision criteria for choosing send-out or in-house testing strategy
- Factors leading to a successful transition from send-out to in-house oncology testing, when appropriate
- Best practices for staffing, data integration, and clinical reporting
Speakers:
Brady Davis, MBA
Senior Vice President, Business Development
Contextual Genomics
Mr. Davis has more than 25 years of leadership experience in the lifesciences, healthcare and software fields. Previous roles have included Vice President, Market Development and Strategy at DNAnexus®, head of strategy and market development
for Illumina® focused on informatics, and the head of healthcare strategy and business development at Oracle. Mr. Davis currently serves on the Board of Directors and Advisory Board of multiple non-profit organizations, including the Global
Alzheimer’s Association Interactive Network, Cancer Informatics for Cancer Centers (Ci4CC), Muscular Dystrophy Association and the University of Washington Center for Commercialization.
Anna Lapuk, PhD
Alliance Manager
Contextual Genomics
Dr. Lapuk brings in nearly 20 years of scientific research experience in application of high resolution molecular profiling technologies and bioinformatics for clinical cancer genomics. In this capacity Dr. Lapuk realizes her passion for translation
of research and development into clinical practice for the ultimate patients benefit.